Table 2.
Medication use during current major depressive episode and lifetime (N=15)
| Current | Lifetime | |||
|---|---|---|---|---|
| Medication/Treatment | N | % | N | % |
| Lithium* | 11 | 73 | 15 | 100 |
| Antidepressants* | ||||
| • SSRI | 5 | 33 | 14 | 93 |
| • Bupropion | 5 | 33 | 12 | 80 |
| • Duloxetine | 3 | 20 | 11 | 73 |
| • Mirtazapine | 3 | 20 | 9 | 60 |
| • Venlafaxine | 1 | 7 | 11 | 73 |
| • TCA | 1 | 7 | 10 | 67 |
| • MAOI | 1 | 7 | 7 | 47 |
| • Trazodone | 1 | 7 | 7 | 47 |
| • Nefazodone | 1 | 7 | 5 | 33 |
| Antipsychotics | ||||
| • Aripiprazole | 3 | 20 | 10 | 67 |
| • Olanzapine*† | 3 | 20 | 7 | 47 |
| • Quetiapine* | 2 | 13 | 10 | 67 |
| • Risperidone | 1 | 7 | 9 | 60 |
| • Ziprasidone | 0 | 0 | 5 | 33 |
| • Conventional Antipsychotics | 0 | 0 | 2 | 13 |
| Anticonvulsants | ||||
| • Lamotrigine* | 5 | 33 | 12 | 80 |
| • Valproate | 4 | 27 | 8 | 53 |
| • Carbamazepine* | 2 | 13 | 6 | 40 |
| • Oxcarbazepine | 0 | 0 | 4 | 27 |
| • Gabapentin | 0 | 0 | 3 | 20 |
| • Topiramate | 0 | 0 | 1 | 7 |
| Somatic Treatments | ||||
| • ECT* | 1 | 7 | 6 | 40 |
| • VNS | 0 | 0 | 1 | 7 |
| Other | ||||
| • Thyroid Augmentation | 4 | 27 | 7 | 47 |
| • Stimulant | 2 | 13 | 6 | 40 |
| • Modafinil* | 0 | 0 | 5 | 33 |
| • Pramipexole* | 0 | 0 | 2 | 13 |
Abbreviations: ECT, electroconvulsive therapy; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; VNS, vagal nerve stimulation.
*
Adequate trial based on the Antidepressant Treatment History Form-modified (ATHF-modified), modified to include adequate trial definition for quetiapine, newer antidepressants, modafinil, pramipexole, and atypical antipsychotic drugs (modified from (33)).
†
6 subjects had failed olanzapine + SNRI/SSRI (fluoxetine/or other SSRI).